ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Alisol B 23-acetate alleviates high-fat diet-induced insulin resistance by activating the SIRT1/FOXO1 axis and PI3K/AKT pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), the most frequent chronic liver disease, is strongly linked to insulin resistance and currently has no effective treatments available. Alisol B 23-acetate (AB23A), a key bioactive component from Alismatis Rhizoma, shows promising lipid-lowering properties, but its impact and mechanisms on MASLD are not fully elucidated. An in vivo model was established via high-fat diet (HFD)-fed mice, and an in vitro model was generated via oleic acid (OA)-induced AML-12 hepatocytes. The efficacy of AB23A was assessed by measuring fasting blood glucose (FBG)/insulin levels, lipid profiles, and hepatic lipid content. Network pharmacology analysis predicted potential targets, molecular docking, molecular dynamics simulations, biolayer interferometry (BLI), and a cellular thermal shift assay (CETSA) were used to validate the binding of AB23A and SIRT1. Protein expression was analyzed via Western blotting, immunohistochemistry, and immunofluorescence staining. AB23A significantly reduced FBG, fasting insulin levels, HOMA-IR, and hepatic lipid accumulation in HFD-fed mice, while simultaneously improving liver function. Network pharmacology analysis combined with experimental validation demonstrated that AB23A directly binds to and activates SIRT1. In vitro, AB23A alleviated OA-induced hepatic steatosis and insulin resistance. Importantly, the SIRT1 inhibitor EX527 abolished the beneficial effects of AB23A, including the upregulation of the p-AMPK, p-ACC, CPT1α, and p-FOXO1, as well as the activation of the PI3K/AKT pathways. This study identified SIRT1 as a direct target of AB23A. AB23A ameliorates hepatic steatosis and insulin resistance by targeting SIRT1, promoting fatty acid oxidation, modulating downstream FOXO1 activity, and coactivating the PI3K/AKT signaling pathway. These findings highlight AB23A as a promising therapeutic candidate for MASLD.
Indexed as
Identifiers
41269296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.